soul trial oral semaglutide cardiovascular outcomes results 2025 nejm The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome NEJM Editorial Fellow Harleen Marwah,

The goal is always sustainable improvement in overall health not rapid or cosmetic weight loss

Brand-name Ozempic is an FDA-approved, pre-filled pen with a specific formulation and extensive clinical trial data

Triple vs Dual Agonist: The Mechanism That Matters The headline difference between these two compounds is one extra receptor

Choosing Between Semaglutide and Tirzepatide Based on Eligibility You May Be Better Suited for Semaglutide If You prefer steady progress You have mild metabolic slowdown You experience digestive sensitivity You fall at the lower end of the eligibility BMI range You May Be Better Suited for Tirzepatide If You struggle with strong appetite dysregulation You have significant insulin resistance You previously plateaued on Semaglutide You have a higher BMI or desire more rapid improvement Realistic Expectations for Eligible Patients Once on a therapeutic dose most patients experience Early appetite changes Steady weekly weight loss Improved blood sugar stability Higher energy and better mood Fifteen to thirty percent reduction in baseline weight over time GLP-1s support long term metabolic resetting when monitored properly